Dynamic monitoring of cell-free DNA levels in glioblastoma patients: a longitudinal study on treatment response

Glioblastoma (GB) is the most aggressive form of malignant glioma, characterized by a low survival rate and minimal improvements in patient outcomes over the past three decades. This study investigates the feasibility of detecting circulating cell-free DNA (cfDNA) and analyses its dynamic fluctuations in a cohort of 59 patients undergoing chemoradiation treatment according to the standardized "Stupp protocol". In our cohort, longitudinal cfDNA levels remained broadly stable at the population level over the follow-up period; however, substantial inter-individual variability in individual trajectories was observed, highlighting the complexity of cfDNA dynamics in GB. At the individual level, longitudinal monitoring revealed that cfDNA levels generally declined following surgery and chemoradiotherapy, yet increased prior to or coinciding with radiological progression, supporting its potential utility as a biomarker for tumour burden estimation and treatment response monitoring. We further developed a cfDNA index model correlating preoperative cfDNA levels with gross tumour volume and clinical target volume, demonstrating a statistically significant association with radiological progression. To the best of our knowledge, this is the first study to propose a mathematically derived cfDNA index in GB. This simple, low-cost, and minimally invasive approach may offer a valuable tool for early risk stratification at diagnosis, complement longitudinal clinical assessment, and support individualized treatment planning and surveillance. Overall, these findings reinforce the potential of cfDNA quantification as an accessible biomarker to advance precision medicine in GB.

Authors

Institutions

Publication Details

Journal
Molecular Biomedicine
Published
2026-11-18
DOI
https://doi.org/10.1186/s43556-026-00669-0
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dynamic monitoring of cell-free DNA levels in glioblastoma patients: a longitudinal study on treatment response

Luís Miguel Pires, Paulo Luz, Francisco José Caramelo, P. Jacinto et al.
1 links
Molecular Biomedicine
Glioma Diagnosis and Treatment
article

Dynamic monitoring of cell-free DNA levels in glioblastoma patients: a longitudinal study on treatment response

Luís Miguel Pires, Paulo Luz, Francisco José Caramelo, P. Jacinto, Joana Barbosa Melo, Isabel M. Carreira, Ilda Patrícia Ribeiro, Pedro Veiga, Mónica Mariano, Leonor Santos, Domingos Roda, Pedro Abreu, José L. Alves, Ana Nascimento, Filipa Oliveira, Paula Alves, Tomás Dinis
article en

Abstract

Glioblastoma (GB) is the most aggressive form of malignant glioma, characterized by a low survival rate and minimal improvements in patient outcomes over the past three decades. This study investigates the feasibility of detecting circulating cell-free DNA (cfDNA) and analyses its dynamic fluctuations in a cohort of 59 patients undergoing chemoradiation treatment according to the standardized "Stupp protocol". In our cohort, longitudinal cfDNA levels remained broadly stable at the population level over the follow-up period; however, substantial inter-individual variability in individual trajectories was observed, highlighting the complexity of cfDNA dynamics in GB. At the individual level, longitudinal monitoring revealed that cfDNA levels generally declined following surgery and chemoradiotherapy, yet increased prior to or coinciding with radiological progression, supporting its potential utility as a biomarker for tumour burden estimation and treatment response monitoring. We further developed a cfDNA index model correlating preoperative cfDNA levels with gross tumour volume and clinical target volume, demonstrating a statistically significant association with radiological progression. To the best of our knowledge, this is the first study to propose a mathematically derived cfDNA index in GB. This simple, low-cost, and minimally invasive approach may offer a valuable tool for early risk stratification at diagnosis, complement longitudinal clinical assessment, and support individualized treatment planning and surveillance. Overall, these findings reinforce the potential of cfDNA quantification as an accessible biomarker to advance precision medicine in GB.

Molecular BiomedicineVol. 7(1)
Instituto Português de Oncologia de Coimbra Francisco Gentil (PT), Hospitais da Universidade de Coimbra (PT), Algarve Biomedical Center (PT), Instituto Português de Oncologia de Coimbra Francisco Gentil (PT), Centro de Investigação em Meio Ambiente Genética e Oncobiologia (PT), Centro de Inovação em Biomedicina e Biotecnologia (PT), Joaquim Chaves Saúde (Portugal) (PT), University of Coimbra (PT)
Liga Portuguesa Contra o Cancro
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon